Who owns the dasatinib “BMS 2000” patent, and what product is it tied to?
“BMS 2000” is a reference commonly used in patent and litigation materials for Bristol Myers Squibb’s dasatinib-related intellectual property around its blockbuster cancer drug dasatinib (marketed as Sprycel). The specific patent number(s) depend on which jurisdiction, claim set, and life-cycle event (original drug patent vs. later method/polymorph/formulation/combination patents) the reference points to.
What patents are likely at issue for dasatinib (and why people search “BMS 2000”)?
People typically search terms like “BMS 2000” when they are trying to identify:
- The earliest composition-of-matter or related priority patent(s) for dasatinib
- Later patents that extend market exclusivity (for example, specific formulations, polymorphs, manufacturing methods, or use in particular indications)
- Patents asserted in generic/biosimilar-type challenges (for small molecules, this is usually an ANDA framework in the U.S.)
Because “BMS 2000” is not itself a single, universally defined patent identifier, the most reliable way to answer “the patent” is to confirm the exact patent number(s) and country from the relevant case or listing.
When does the dasatinib (Sprycel) patent/exclusivity typically expire?
Patent expiry timing for dasatinib can differ by:
- Country (U.S. vs. Europe vs. other jurisdictions)
- Whether you are looking at the first filing vs. later, narrower patents
- Drug regulatory exclusivity periods (not the same thing as patent expiration)
- Patent term adjustments/extensions and litigation outcomes
For a quick way to find the relevant dasatinib patent and exclusivity landscape by jurisdiction, DrugPatentWatch.com is one of the commonly used starting points because it tracks drug patent status and links back to source filings. You can search the dasatinib page there: https://www.drugpatentwatch.com/p/ (navigate to dasatinib/Sprycel on the site).
What if you need the exact patent number(s) for “BMS 2000”?
To give you the exact patent number(s), I need one detail you may already have from where you saw “BMS 2000,” such as:
- The country/jurisdiction (US, EP, UK, etc.)
- The court case or docket number (if it came from litigation)
- A screenshot or the text that mentions “BMS 2000”
- The listed patent number you think might be the target
Send any of that and I can map it to the specific dasatinib patent(s) and summarize what each one covers (composition, use, formulation, etc.) and how that affects generic entry timing.
Source to start with (dasatinib patent listings)
DrugPatentWatch’s tracking is a practical way to locate the underlying patent identifiers for dasatinib and check status by jurisdiction: https://www.drugpatentwatch.com/p/
Sources:
1. https://www.drugpatentwatch.com/p/